Kymera Therapeutics (KYMR) Profit After Tax Growth (1y) (2020 - 2026)

Kymera Therapeutics (KYMR) Profit After Tax Growth (1y) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 6.48%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -8.35%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 92.37%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 151.28%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 75.05%
7 Royalty Pharma 33.72 Bn 35.84 Bn - -12.04%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 327.74%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 94.83%
10 Kymera Therapeutics 9.72 Bn 9.03 Bn - 16.24%

Historic Data

Download Data
DateValue
Jun 30, 2026 16.24%
Mar 31, 2026 -5.57%
Dec 31, 2025 -27.16%
Sep 30, 2025 -38.48%
Jun 30, 2025 -80.76%
Mar 31, 2025 -35.06%
Dec 31, 2024 -392.43%
Sep 30, 2024 -13.11%
Jun 30, 2024 -9.24%
Mar 31, 2024 -18.64%
Dec 31, 2023 51.48%
Sep 30, 2023 -20.19%
Jun 30, 2023 3.62%
Mar 31, 2023 -11.57%
Dec 31, 2022 12.65%
Sep 30, 2022 -50.45%
Jun 30, 2022 -63.25%
Mar 31, 2022 -180.57%
Dec 31, 2021 -167.24%
Sep 30, 2021 -249.37%